WO/2015/152761 DEVICE FOR ELECTROLYTIC PRODUCTION OF A GASEOUS MIXTURE OF HYDROGEN AND OXYGEN||WO||08.10.2015|
||PCT/RU2014/000274||KUZNETSOV, Alexandr Urievich||KUZNETSOV, Alexandr Urievich|
This invention relates to the field of electrochemistry. The present device for the electrolytic production of a gaseous mixture of hydrogen and oxygen contains an electrolyser which comprises a housing containing electrodes in the form of plates, said electrodes being electrically connected to a power supply. The electrodes are configured in the form of a set of spaced apart stainless steel plates with vertical and horizontal saw cuts in the surfaces thereof and with openings for the circulation of electrolyte and the removal of gases, said openings being provided in each plate so as to be non-coaxial with the openings in the adjacent plates. The electrolyte is a weak solution of water and sodium hydroxide. An electrolyte receptacle is configured as a closed and sealed receptacle with an inlet for filling the space inside the receptacle with electrolyte so that an empty space is formed above the surface of the electrolyte; the receptacle is connected to a channel for removing a mixture of gas and water from the electrolyser, and a channel for collecting a gaseous mixture of hydrogen and oxygen, which has a water lock mounted therein, is connected to the empty space of the electrolyte receptacle. At the same time, the electrolyser housing contains at least one source for emitting ultrasonic radiation into the water-based electrolyte in order to weaken the molecular bonds of said electrolyte; the housing also contains a source of ultraviolet radiation for acting on the electrolyte.
WO/2014/170071 WEAR INDICATOR IN A COMPOSITE SYSTEM OF REFRACTORY CERAMIC STONES||WO||23.10.2014|
||PCT/EP2014/054921||REFRACTORY INTELLECTUAL PROPERTY GMBH & CO. KG||KLIKOVICH, Michael|
The invention relates to a wear indicator in a composite system of refractory ceramic stones.
WO/2014/120981 COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS||WO||07.08.2014|
||PCT/US2014/013953||GILEAD PHARMASSET LLC||CHAL, Ben|
Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
WO/2014/111584 METHODS OF TREATMENT OF FIBROSIS AND CANCERS||WO||24.07.2014|
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5- dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one for treating fibrotic diseases and cancers.
WO/2014/102778 AGENTS FOR TREATING GENETIC DISEASES RESULTING FROM NONSENSE MUTATIONS, AND METHODS FOR IDENTIFYING THE SAME||WO||03.07.2014|
||PCT/IL2013/051058||RAMOT AT TEL-AVIV UNIVERSITY LTD.||ROSIN-ARBESFELD, Rina|
Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof.
WO/2014/097041 ARYL AND HETEROARYL FUSED LACTAMS||WO||26.06.2014|
||PCT/IB2013/060682||PFIZER INC.||EDWARDS, Martin Paul|
This invention relates to compounds of general Formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
WO/2014/100323 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE||WO||26.06.2014|
||PCT/US2013/076367||GILEAD SCIENCES, INC.||JIN, Haolun|
Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Ζ1 and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
WO/2014/100500 ANTIVIRAL COMPOUNDS||WO||26.06.2014|
||PCT/US2013/076734||GILEAD SCIENCES, INC.||BACON, Elizabeth M.|
The disclosure is related to compounds having a polycyclic core and at least one 2,6-dimethyltetrahydro-2H-pyran-4-yl, 4- methyltetrahydro-2H-pyran-4-yl, or tetrahydro-2H-pyran-3-yl capping group, which compounds are provided for use in pharmaceutical compositions and methods for treating hepatitis C (HCV).
WO/2014/091368 IMIDAZOPYRIDAZINE DERIVATIVES AS GABAA RECEPTOR MODULATORS||WO||19.06.2014|
||PCT/IB2013/060631||PFIZER LIMITED||OMOTO, Kiyoyuki|
Chemical Compounds The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5- c]pyridazine derivatives of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R 2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
WO/2014/087298 NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS||WO||12.06.2014|
||PCT/IB2013/060381||PFIZER INC.||ANDERSON, James, Thomas|
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or –CR0 --, where R0 is hydrogen, C1 -C6 linear or branched chain alkyl, etc., Z is –CRe --, or, –N--, where Re is hydrogen, C1 -C6 linear or branched chain alkyl,etc.; R1 is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1 -C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1 -C6 linear or branched chain alkyl, etc.;. R5 and R6 are independently hydrogen or C1 -C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1 -C6 linear or branched chain alkyl, etc.; Q is --CO--, --(CH2 )q --, --(CHRS )q --, or –(CRS Rt )q--, where RS and Rt are independently C1 -C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.